Cybin Provides Corporate Update on Upcoming Clinical Milestones
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Business Wire
- Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder (“MDD”) expected imminently -- 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 -- Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder (“GAD”) expected year-end 2024 or early Q1 2025 -- Strengthened R&D team with addition of experienced drug development leaders Dr. Atul R. Mahableshwarkar, and Dr. Tom Macek, as program leads for CYB003 and CYB004, respectively - TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones.“We are making rapid advancements in our two lead clinical programs – CYB003, our proprietary deuterated psilocin program in develop
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics” [Yahoo! Finance]Yahoo! Finance
- Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitBusiness Wire
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $114.00 to $96.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin Provides Corporate Update on Upcoming Clinical Milestones [Yahoo! Finance]Yahoo! Finance
- 'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale [Seeking Alpha]Seeking Alpha
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- 9/20/24 - Form 6-K
- CYBN's page on the SEC website